Navigate the Compliance Universe

## Compliance Today - December 2018 Considerations for prescribing opioids

by Sharon Parsley, JD, MBA, CHC, CHRC
Sharon Parsley (sharonparsley@outlook.com) is President and Managing Director at Quest Advisory Group, LLC in Ocala, FL.

Provisional data from the Centers for Disease Control (CDC) for the 12-month period ending July $2017{ }^{[1]}$ showed mixed results in the battle to prevent opioid overdose deaths, with some states showing improvement, while others showed a marked increase in total drug-attributable deaths. With that said, it is difficult to refute that the United States remains mired in an opioid overdose epidemic, with 42,000 deaths during 2016[2] arising from opioid overdose, including prescription pain relievers, heroin, and fentanyl. By one CDC estimate, the aggregate "economic burden" associated with prescription opioid misuse alone is in the range of $\$ 78.5$ billion annually in healthcare expenditures, lost worker productivity, addiction treatment, and criminal justice costs.[3]

This document is only available to members. Please $\log$ in or become a member.

Become a Member Login

[^0]
[^0]:    Copyright © 2024 by Society of Corporate Compliance and Ethics (SCCE) \& Health Care Compliance Association (HCCA). No claim to original US Government works. All rights reserved. Usage is governed under this website's Terms of Use.

